Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma.
Elranatamab is approved by the Food and Drug Administration as a treatment option for patients with heavily pretreated R/R MM. Further studies are warranted to identify the optimal treatment strategy for elranatamab and other bispecific antibodies in the management of R/R MM.